ABSTRACT
The cure for restenosis has been the Holy Grail of interventional cardiology since the advent of coronary angioplasty in the late 1970s. The development of stents improved the durability of angioplasty, but in-stent restenosis was a major problem for patients and the physicians. To deliver drugs locally on stents that prevent restenosis is a revolutionary advance. Percutaneous revascularization technology has leaped forward, dramatically altering clinical practices, with what may be the single most important advance in the history of cardiology. There are new delivery platforms and new drugs currently being tested. Despite the continuing advancement, there was a need to collate in a single text, information on drug eluting stents for coronary disease. Chris White and colleagues have put together a logically organized text that progresses from theory to practice, and addresses pharmacologic, technical and strategic issues as they relate to the placement of coronary drug-eluting stents.
TABLE OF CONTENTS
part |2 pages
PART I B
chapter 3|12 pages
Drug-eluting stent platforms: antiproliferative drugs and polymer coatings
part |2 pages
Part II Treatment of Restenosis
chapter 4|8 pages
Trials of oral drug therapy to reduce restenosis Jose A Silva
chapter 5|16 pages
Non-stent devices to reduce restenosis Srinivasa P Potluri and Jose A Silva
chapter 6|10 pages
Clinical trials of bare metal stents to reduce restenosis Jose A Silva
part |2 pages
Part III Clinical Experience with Drug-Eluting Stents
chapter 7|12 pages
Clinical trials: bare metal stents versus drug-eluting stents
chapter 8|14 pages
Broader indications (off-label use) for coronary drug-eluting stents
chapter 9|10 pages
Complications related to drug-eluting stents Jose A Silva
part |2 pages
Part IV Optimal Patient Management and Selection for
chapter 10|8 pages
Patient selection criteria for drug-eluting stents
chapter 11|10 pages
Optimal antiplatelet and anticoagulation therapy for drug-eluting stents
chapter 12|10 pages
Optimal deployment strategies for drug-eluting stents Georges A Feghali and Bahji N Khuri
part |2 pages
Part V Cost–Benefit Analysis and Future Strategies for